Literature DB >> 8887498

Effect of natural sequence variation at the H-2Ld-restricted CD8+ T cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T cell recognition.

P A Lyons1, J E Allan, C Carrello, G R Shellam, A A Scalzo.   

Abstract

The amino acid sequence YPHFMPTNL of pp89, the ie1-encoded product of murine cytomegalovirus (MCMV; Smith strain), constitutes an immunodominant T cell epitope recognized in association with H-2Ld. Nucleotide sequencing of MCMV isolates derived from wild mice identified variation between amino acids 147-192 of pp89 in 19 of 27 isolates, including the region encompassing the CTL epitope (amino acid residues 168-176). Four groups of isolates with naturally occurring variant sequences for the CTL epitope were defined: (1) YPHFMPPNL; (2) YPHFMPPSL; (3) YPHFIPPSL; and (4) YLDFMPPNL. The remaining isolates, and the laboratory strains K181 and Vancouver, showed complete identity with the Smith strain. Polyclonal pp89 (Smith strain)-specific CTL only weakly recognized target cells infected with MCMV from most variant groups. No lysis of cells infected with isolate N1 from group 4 was detected. Analyses of cross-reactive recognition of YPHFMPTNL peptide-coated targets by CTL primed with variant MCMV isolates showed that the group 2 and 3 isolates, G4 and K6, respectively, but not the group 4 isolate N1, elicited CTL that exhibited a cross-reactive response. Furthermore, while the group 2 and 3 isolates G4 and K6 were able to prime CTL responses that displayed reactivity to homologous pp89 variant nonapeptides, the group 4 isolate N1 failed to do so. Finally, while immunization of mice with the nonapeptide YPHFMPTNL conferred significant protection against the laboratory strain K181 [correction of Kl81], no evidence of protection was observed for the group 2 and 4 variants G4 and N1, respectively. These observations raise the possibility that clinical isolates of HCMV may also differ in sequence from potential vaccine strains at immunodominant epitopes for CD8+ T cells thus reducing the efficacy of vaccination.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887498     DOI: 10.1099/0022-1317-77-10-2615

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

2.  The 20S proteasome splicing activity discovered by SpliceMet.

Authors:  Juliane Liepe; Michele Mishto; Kathrin Textoris-Taube; Katharina Janek; Christin Keller; Petra Henklein; Peter Michael Kloetzel; Alexey Zaikin
Journal:  PLoS Comput Biol       Date:  2010-06-24       Impact factor: 4.475

3.  Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination.

Authors:  Rafaela Holtappels; Christian O Simon; Michael W Munks; Doris Thomas; Petra Deegen; Birgit Kühnapfel; Torsten Däubner; Simone F Emde; Jürgen Podlech; Natascha K A Grzimek; Silke A Oehrlein-Karpi; Ann B Hill; Matthias J Reddehase
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

4.  Laboratory strains of murine cytomegalovirus are genetically similar to but phenotypically distinct from wild strains of virus.

Authors:  L M Smith; A R McWhorter; L L Masters; G R Shellam; A J Redwood
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

Review 5.  Reverse genetics modification of cytomegalovirus antigenicity and immunogenicity by CD8 T-cell epitope deletion and insertion.

Authors:  Niels A W Lemmermann; Kai A Kropp; Christof K Seckert; Natascha K A Grzimek; Matthias J Reddehase
Journal:  J Biomed Biotechnol       Date:  2010-12-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.